Table 3.
Summary of tumor response
| Durvalumab + EP (n = 18) | EP (n = 16) | |
|---|---|---|
| Unconfirmed objective response, n (%)a | 17 (94) | 13 (81) |
| Odds ratio (95% CI) | 3.92 (0.44–84.49) | |
| Confirmed objective response, n (%)a | 16 (89) | 11 (69) |
| Odds ratio (95% CI) | 3.64 (0.65–28.75) | |
| Best unconfirmed response, n (%)a | ||
| Complete | 0 | 0 |
| Partial | 17 (94) | 13 (81) |
| Stable disease ≥ 6 weeks | 1 (6) | 3 (19) |
| Progressive disease | 0 | 0 |
| Best reduction from baseline in target lesion size, %a | ||
| Mean ± SD | – 61.6 ± 19.59 | – 49.6 ± 21.88 |
| Median (range) | – 63.55 (– 87.7 to – 8.9) | – 53.90 (– 82.4 to 1.6) |
| Median (95% CI) duration of response, monthsb | 3.1 (2.5–5.1) | 3.5 (3.3–5.0) |
| Remaining in response, %b | ||
| At 6 months | 12.5 | 9.1 |
| At 12 months | 6.3 | 0 |
EP platinum-etoposide, RECIST Response Evaluation Criteria in Solid Tumors
aInvestigator-assessed objective response per RECIST v1.1
bCalculated using the Kaplan–Meier method; based on confirmed responses